When to use new antibacterials in Gram-positive infections?

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1260, 2000-01, pp. : 3-3

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Penetration of Antibacterials into Bone: What Do We Really Need to Know for Optimal Prophylaxis and Treatment of Bone and Joint Infections?

By Pea Federico  

Clinical Pharmacokinetics, Vol. 48, Iss. 2, 2009-01 ,pp. : 125-127

Adis International

Access to resources Recommend Favorite

Daptomycin - a new option for resistant Gram-positive infections

By  

Inpharma, Vol. 1, Iss. 1342, 2002-01 ,pp. : 9-11

Adis International

Access to resources Recommend Favorite

Outpatient therapy an option in CNS infections?

By  

Inpharma, Vol. 1, Iss. 1224, 2000-01 ,pp. : 16-16

Adis International

Access to resources Recommend Favorite

Linezolid: A Pharmacoeconomic Review of its Use in Serious Gram-Positive Infections

By Plosker Greg L.   Figgitt David P.  

PharmacoEconomics, Vol. 23, Iss. 9, 2005-01 ,pp. : 945-964

Adis International

Access to resources Recommend Favorite

Quinupristin/Dalfopristin: A Review of its Use in the Management of Serious Gram-Positive Infections

By Lamb H.M.   Figgitt D.P.   Faulds D.  

Drugs, Vol. 58, Iss. 6, 1999-12 ,pp. : 1061-1097

Adis International

Access to resources Recommend Favorite